You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1579 Results
Regimen
Cancer Type:
Gynecologic, 
Cervix
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative
Drugs Used:
PACLitaxel,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
riTUXimab,
riTUXimab (subcut),
prednisone,
vinCRIStine,
DOXOrubicin,
cyclophosphamide,
iBRUtinib (Unfunded),
CISplatin,
cytarabine,
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025
Our Comprehensive Cancer Biomarker Testing Program supports patient management through the testing of diagnostic, predictive and prognostic markers....

Pages